Question · Q4 2025
Alexa asked about the increasing role of AI in R&D processes, specifically if Schrödinger has observed changes in conversations with pharma customers and if they are leveraging Schrödinger's solutions. She questioned if Schrödinger is an AI winner or if pharma is shifting focus to new solutions from companies like Anthropic or OpenAI. She also inquired about the impact of two largest customers being acquired, asking if usage would disappear or if it could lead to broader adoption within major pharma acquirers.
Answer
Ramy Farid, CEO, views agentic AI as a tailwind, increasing demand for Schrödinger's software due to its throughput-based licensing model and ability to address the know-how barrier for platform adoption. He mentioned working with Anthropic to integrate agentic AI. Richie Jain, CFO, considered the customer acquisitions a positive development, reflecting the impact of Schrödinger's predict-first approach, noting that throughput and relationships were largely retained with the acquiring companies.
Ask follow-up questions
Fintool can predict
SDGR's earnings beat/miss a week before the call